Health Canada
Santé Canada

Health Products and Food Branch
Direction générale des produits de santé et des aliments

Biologic and Radiopharmaceutical Drugs Directorate
100 Eglantine Driveway
LCDC Building,
Tunney's Pasture, A.L. 0601C
Ottawa, Ontario
K1A 0K9

September 19, 2024

**Dossier ID: HC6-024-e278519**
**Control #: 288077**

## TERMS AND CONDITIONS

Further to the Terms and Conditions Letter issued for Nuvaxovid XBB.1.5 (COVID-19 vaccine (recombinant protein, adjuvanted)) on December 5, 2023, the terms and conditions have been amended. In accordance with section C.01.014.21 (1.1) of the *Food and Drug Regulations*, the following terms and conditions are imposed on Drug Identification Number 02543656 assigned to Nuvaxovid (COVID-19 vaccine (recombinant protein, adjuvanted)):

| | **Terms and Conditions** | **Issued** (YY/MM/DD) | **Status** |
|---|---|---|---|
| **CLINICAL:** | | | |
| 1 | Provide the results from the blinded crossover period including safety and efficacy data for 24 months from adult participants after the second dose from Study 2019nCoV-301, when the data become available as a Supplement to a New Drug Submission (SNDS). | 2024-09-19 | Ongoing |
| 2 | Provide the results from the blinded crossover period including safety and efficacy data for 12 months from participants after the second dose from Study 2019nCoV-302, when the data become available. | 2023-12-05 | Closed |
| 3 | Provide the final safety, efficacy, and immunogenicity results from the adolescent participants from Study 2019nCoV-301, when the data become available as a Supplement to a New Drug Submission (SNDS). | 2024-09-19 | Ongoing |
| 4 | Update the Product Monograph with information on the pregnancy registry, when the registry is in effect and the weblink is live. The text provided in the clarification request dated 2022-01-14 should be followed for this update. | 2023-12-05 | Closed |
| 5 | Provide data regarding protection against current and emerging variants of concern, when available. | 2023-12-05 | Ongoing |
| 6 | Final report of Study 2019nCoV-501 should be provided once available. | 2023-12-05 | Closed |

Canada

| | | | |
|---|---|---|---|
| 7 | Vaccine effectiveness following vaccination with Nuvaxovid should be provided once the data become available. | 2024-09-19 | Ongoing |
| 8 | Provide interim analyses at 1 month of the immunogenicity data from Clinical Study 2019nCoV-313 Part 1 pertaining to the primary, secondary, and exploratory immunogenicity objectives and endpoints as soon as it becomes available as a Supplement to a New Drug Submission (SNDS)/Level II – Supplement. | 2023-12-05 | Closed |
| 9 | Provide interim analyses at 1 month of the immunogenicity data from Clinical Study 2019nCoV-313 Part 2 pertaining to the primary, secondary, and exploratory immunogenicity objectives and endpoints as soon as it becomes available as a Supplement to a New Drug Submission (SNDS). | 2023-12-05 | Ongoing |
| 10 | Provide interim analyses at 1 month of the safety data from Clinical Study 2019nCoV-313 Part 1 pertaining to the primary, secondary, and exploratory safety objectives and endpoints as soon as it becomes available as a Supplement to a New Drug Submission (SNDS)/Level II – Supplement. | 2023-12-05 | Closed |
| 11 | Provide interim analyses at 1 month of the safety data from Clinical Study 2019nCoV-313 Part 2 pertaining to the primary, secondary, and exploratory safety objectives and endpoints as soon as it becomes available as a Supplement to a New Drug Submission (SNDS). | 2023-12-05 | Ongoing |
| 12 | Provide final analyses at 6 months of the immunogenicity and safety data from Clinical Study 2019nCoV-313 Part 1 pertaining to the primary, secondary, and exploratory immunogenicity/safety objectives and endpoints as soon as it becomes available as Post Clearance Data. | 2024-09-19 | Ongoing |
| 13 | Provide final analyses at 6 months of the immunogenicity and safety data from Clinical Study 2019nCoV-313 Part 2 pertaining to the primary, secondary, and exploratory immunogenicity/safety objectives and endpoints as soon as it becomes available as Post Clearance Data. | 2024-09-19 | Ongoing |
| 14 | Provide final analyses through 6 months of the immunogenicity and safety data from Clinical Study 2019nCoV-314 pertaining to the primary, secondary, and exploratory immunogenicity/ safety objectives and endpoints, along with a post-hoc analysis of the neutralizing antibodies at 28 days post-dose of the "per-protocol immunogenicity" population compared to the historical control of adolescents that received NUVAXOVID (prototype vaccine) as a third booster dose following the NUVAXOVID primary series and a post-hoc analysis of the safety, namely, 7-day reactogenicity (local and systemic adverse event) and 28-day treatment emergent adverse events, in the safety analysis set population that received NUVAXOVID XBB.1.5 compared to the historical control of adolescents that received NUVAXOVID (prototype vaccine) as a third booster dose following the NUVAXOVID primary series, as soon as it becomes available as a Supplement to a New Drug Submission (SNDS). | 2024-09-19 | Ongoing |
| **PHARMACOVIGILANCE:** | | | |

| | | | |
|---|---|---|---|
| 1 | Novavax Inc. is required to submit Periodic Safety Update Reports (PSURs)/ Periodic Benefit Risk Evaluation Reports (PBRERs) every 6 months for NUVAXOVID XBB.1.5, unless otherwise determined by Health Canada. | 2023-12-05 | Closed |
| 2 | Novavax Inc. is required to submit an updated core RMP with the Canadian Addendum in a timely manner if a safety issue is identified that requires immediate regulatory action or as requested by Health Canada. The RMP format should follow the guidance (Guidance Document Submission of Risk Management Plans and Follow-Up Commitments) and should include the following:<br>a. A safety specification that details the identified risks, potential risks, and missing information for NUVAXOVID XBB.1.5;<br>b. A pharmacovigilance plan that details specific measures to be taken to identify and report safety issues in COVID-19 patients, including adverse reaction reporting, periodic reports, and ongoing/ planned studies; and<br>c. A risk minimization plan, if applicable, to manage risks that may require additional measures beyond those considered standard. | 2023-12-05 | Closed |
| 3 | Novavax Inc. is required to submit interim and final reports for post-authorization studies 2019nCoV-402 and 2019nCoV-404. | 2023-12-05 | Ongoing |
| **LABELLING:** | | | |
| 1 | Novavax Inc. to provide a summary of the changes made to the website for Health Canada's review with each update.<br>a. Novavax Inc. to attest that the content of the website is consistent with the approved Canadian-specific labelling information for NUVAXOVID (COVID-19 Vaccine (recombinant protein, adjuvanted)) in French and English. The website content related to the appropriate storage & handling and preparation & administration of NUVAXOVID (COVID-19 Vaccine (recombinant protein, adjuvanted)) should be aligned with information in the Product Monograph.<br>b. For revisions to the website design and layout related to updates to the indication, use or presentation of the vaccine, Novavax Inc. commits to providing final screenshots of relevant components of the electronic platform (linked to any foreign or Canadian specific NUVAXOVID (COVID-19 Vaccine (recombinant protein, adjuvanted)) labels dispensed in Canada), containing the approved Canadian-specific labelling information for NUVAXOVID (COVID-19 Vaccine (recombinant protein, adjuvanted)) in French and English for Health Canada's records, following review and approval by Pharmaceutical Advertising Advisory Board (PAAB). | 2024-09-19 | Ongoing |
| 2 | Novavax Inc. is requested to develop and distribute a company-led customer communication, in English and French, should a decision be made to import non-Canadian labelled supplies for Canadian sites. The customer communication should aim to inform healthcare professionals that Novavax Inc. will delay the implementation of Canadian-specific inner/outer labels following | 2024-09-19 | Ongoing |

| | | | |
|---|---|---|---|
| | approval for NUVAXOVID. (COVID-19 Vaccine (recombinant protein, adjuvanted)), and that interim inner/outer labels will be used for the short term. Please note the following:<br>a. Novavax Inc. should consider including images and texts of these labels in the customer communication and clearly outline all deviations from Canadian requirements;<br>b. The customer communication should direct healthcare professionals to the electronic platform where they can find information about the approved Canadian-specific labelling in both official languages<br>c. The customer communication should not resemble a Health Canada-endorsed Health Product Risk Communication and should not reflect a red banner at the top of the document. A company led risk communication may take the form of a letter carrying the company letterhead, for example.<br>The company-led customer communication does not require review by Health Canada; however, Novavax Inc. is welcome to seek courtesy feedback from BRDD. Novavax Inc. is expected to exercise due discretion to ensure prompt finalization and dissemination of the customer communication. Please provide a copy of the final, signed customer communication in English and French via eCTD once available. | | |
| 3 | Novavax Inc. to commit to implementing Canadian specific bilingual labelling for NUVAXOVID (COVID-19 Vaccine (recombinant protein, adjuvanted)) Drug Identification Numbers (DINs) currently marketed in Canada, to be submitted in the agreed upon timeline. Health Canada should be kept informed of estimated timelines and proposed strategies concerning the implementation of Canadian-specific bilingual labels. During the period prior to implementation of the Canadian-specific bilingual labeling, Canadian reference labels should be made available to healthcare professionals. | 2023-12-05 | Ongoing |